Stock Report: Affymax Inc. (AFFY) Report Updated: May 20, 2013 | Print This Page
Report Features:
Stock Analysis
Rating: Monthly View
| A |  |
 |
|
|
|
|
|
|
|
|
 |
 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B | ||||||||||||
| C | ||||||||||||
| D | ||||||||||||
| F | ||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Rating: Weekly View
| This Week: | D  no change |
|---|---|
| Last Week: | D  upgrade |
| Two Weeks Ago: | N no change |
Company Profile
Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions in the United States. It offers OMONTYS (peginesatide) Injection for the treatment of anemia in chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. The company has strategic alliance agreement with Takeda Pharmaceutical Company Limited to develop and commercialize OMONTYS. Affymax, Inc. was founded in 2001 and is headquartered in Palo Alto, California.
Recent News: Affymax Inc.
| 2012-10-17 08:00:00 | Affymax and Takeda Announce OMONTYS® Data Presentations at the American Society of Nephrology Kidney Week 2012 |
| 2012-10-03 00:00:00 | Initial statement of beneficial ownership of securities - Form 3 |
| 2012-10-03 00:00:00 | Report of unscheduled material events or corporate changes - Form 8-K |
| 2012-10-02 08:00:00 | Affymax Appoints Karin L. Walker as Vice President of Finance and Chief Accounting Officer |
| 2012-09-13 08:00:00 | Affymax to Present at the UBS 2012 Global Life Sciences Conference |
ADVERTISEMENT
My Portfolios (View All)
Save your portfolio—or a few for that matter—and check up on your stocks 24/7! Log in here.
Louis Navellier's Portfolios
- Blue Chip GrowthTop blue chips
- Emerging GrowthTop small-caps
- Ultimate GrowthFastest-moving
- Platinum GrowthElite Model Portfolio
Most Popular Stocks
Daily Leader Boards
Louis' Weekly Ratings
ADVERTISEMENT